{"id":"NCT04058353","sponsor":"Vertex Pharmaceuticals Incorporated","briefTitle":"A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)","officialTitle":"A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-08-28","primaryCompletion":"2020-06-12","completion":"2020-06-12","firstPosted":"2019-08-15","resultsPosted":"2021-07-02","lastUpdate":"2021-07-02"},"enrollment":271,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Cystic Fibrosis"],"interventions":[{"type":"DRUG","name":"ELX/TEZ/IVA","otherNames":["VX-445/VX-661/VX-770","elexacaftor/tezacaftor/ivacaftor"]},{"type":"DRUG","name":"IVA","otherNames":["VX-770","ivacaftor"]},{"type":"DRUG","name":"TEZ/IVA","otherNames":["VX-661/VX-770","tezacaftor/ivacaftor"]}],"arms":[{"label":"Control: IVA or TEZ/IVA","type":"ACTIVE_COMPARATOR"},{"label":"TC: ELX/TEZ/IVA","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the efficacy, safety and pharmacodynamics of elexacaftor (ELX, VX-445) in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are heterozygous for F508del and a gating or residual function mutation (F/G and F/RF genotypes).","primaryOutcome":{"measure":"Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for ELX/TEZ/IVA Group","timeFrame":"From Baseline Through Week 8","effectByArm":[{"arm":"TC: ELX/TEZ/IVA","deltaMin":3.7,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":93,"countries":["United States","Australia","Belgium","Canada","Denmark","France","Germany","Ireland","Israel","Italy","Netherlands","Spain","United Kingdom"]},"refs":{"pmids":["34437784"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":126},"commonTop":["Headache","Cough","Sputum increased","Diarrhoea","Infective pulmonary exacerbation of cystic fibrosis"]}}